Acción ZLAB ZAI LAB LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Zai Lab Limited

Acciones

ZLAB

US98887Q1040

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 05/06/2024 		Varia. Cinco días. Varia. 1 de enero.
19,09 USD -1,04 % Gráfico intradía de Zai Lab Limited +6,29 % -30,15 %
04/06 Los valores tecnológicos y financieros lideran la renta variable asiática negociada en EE.UU. mientras los recibos de depósito estadounidenses caen con fuerza el martes MT
24/05 La renta variable asiática negociada en EE.UU. como recibos de depósito estadounidenses tiende al alza en la sesión del viernes y termina la semana a la baja MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Zai Lab Announces Participation in May and June Investor Conferences
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro
Zai Lab's Cancer Drug Gets NDA Approval in China
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ZLAB
  4. Noticias Zai Lab Limited
  5. Otros idiomas
-40% Prolongación excepcional: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA